Literature DB >> 9636555

Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.

E S Woodle1, J A Bluestone, R A Zivin, L K Jolliffe, J Auger, D Xu, J R Thistlethwaite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9636555     DOI： 10.1016/s0041-1345(98)00278-4

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  9 in total

Review 1.  Challenges in the pursuit of immune tolerance.

Authors:  Gerald T Nepom; E William St Clair; Laurence A Turka
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

2.  Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics.

Authors:  Robert V House; Thomas A Broge; Todd J Suscovich; Doris M Snow; Milan T Tomic; Genevieve Nonet; Kamaljit Bajwa; Guangyu Zhu; Zachary Martinez; Kyal Hackett; Christopher G Earnhart; Nicole M Dorsey; Svetlana A Hopkins; Dalia S Natour; Heather D Davis; Michael S Anderson; Melicia R Gainey; Ronald R Cobb
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

3.  Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Authors:  Simona Cernea; Kevan C Herold
Journal:  Clin Immunol       Date:  2010-02       Impact factor: 3.969

Review 4.  Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

Authors:  Mariela Glandt; Kevan C Herold
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

5.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Authors:  Kevan C Herold; Joshua B Burton; Fleur Francois; Ena Poumian-Ruiz; Mariela Glandt; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

6.  Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Authors:  Howard R Seay; Amy L Putnam; Judit Cserny; Amanda L Posgai; Emma H Rosenau; John R Wingard; Kate F Girard; Morey Kraus; Angela P Lares; Heather L Brown; Katherine S Brown; Kristi T Balavage; Leeana D Peters; Ashley N Bushdorf; Mark A Atkinson; Jeffrey A Bluestone; Michael J Haller; Todd M Brusko
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-24       Impact factor: 6.698

Review 7.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

8.  A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.

Authors:  Ronald R Cobb; Joseph Nkolola; Pavlo Gilchuk; Abishek Chandrashekar; Jingyou Yu; Robert V House; Christopher G Earnhart; Nicole M Dorsey; Svetlana A Hopkins; Doris M Snow; Rita E Chen; Laura A VanBlargan; Manuel Hechenblaickner; Brian Hoppe; Laura Collins; Milan T Tomic; Genevieve H Nonet; Kyal Hackett; James C Slaughter; Mark G Lewis; Hanne Andersen; Anthony Cook; Michael S Diamond; Robert H Carnahan; Dan H Barouch; James E Crowe
Journal:  Med (N Y)       Date:  2022-02-03

9.  Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.

Authors:  Debra T Chao; Xiaohong Ma; Olga Li; Hyunjoo Park; Debbie Law
Journal:  Immunol Invest       Date:  2009       Impact factor: 3.657
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.